Adina M. Hughes
Early Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Micronucleus quantification from whole-slide haematology images using AI serves as a translatable pharmacodynamic biomarker for DNA damage response inhibitors.
Journal: Scientific reports
Published: October 15, 2025
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Journal: Journal for immunotherapy of cancer
Published: February 21, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 19, 2022
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Journal: Cancer research
Published: September 06, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Journal: Molecular cancer therapeutics
Published: November 10, 2020
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 25, 2020
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Journal: Journal for immunotherapy of cancer
Published: May 27, 2019
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Journal: Molecular cancer therapeutics
Published: December 20, 2018
Last Updated: 09/26/2026